- Home
- BRID vs GNTA Comparison
BRID vs GNTA Comparison
Compare BRID & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRID
- GNTA
- Stock Information
- Founded
- BRID 1932
- GNTA 2014
- Country
- BRID United States
- GNTA Italy
- Employees
- BRID N/A
- GNTA N/A
- Industry
- BRID Specialty Foods
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRID Consumer Staples
- GNTA Health Care
- Exchange
- BRID Nasdaq
- GNTA Nasdaq
- Market Cap
- BRID 70.3M
- GNTA 81.2M
- IPO Year
- BRID N/A
- GNTA 2021
- Fundamental
- Price
- BRID $7.83
- GNTA $3.88
- Analyst Decision
- BRID
- GNTA Strong Buy
- Analyst Count
- BRID 0
- GNTA 1
- Target Price
- BRID N/A
- GNTA $25.00
- AVG Volume (30 Days)
- BRID 2.1K
- GNTA 5.3K
- Earning Date
- BRID 06-02-2025
- GNTA 01-01-0001
- Dividend Yield
- BRID N/A
- GNTA N/A
- EPS Growth
- BRID N/A
- GNTA N/A
- EPS
- BRID N/A
- GNTA N/A
- Revenue
- BRID $224,673,000.00
- GNTA N/A
- Revenue This Year
- BRID N/A
- GNTA N/A
- Revenue Next Year
- BRID N/A
- GNTA N/A
- P/E Ratio
- BRID N/A
- GNTA N/A
- Revenue Growth
- BRID N/A
- GNTA N/A
- 52 Week Low
- BRID $7.52
- GNTA $2.79
- 52 Week High
- BRID $14.69
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- BRID 46.08
- GNTA 39.03
- Support Level
- BRID $7.71
- GNTA $3.70
- Resistance Level
- BRID $8.09
- GNTA $6.12
- Average True Range (ATR)
- BRID 0.21
- GNTA 0.43
- MACD
- BRID 0.01
- GNTA -0.07
- Stochastic Oscillator
- BRID 44.68
- GNTA 7.23
About BRID Bridgford Foods Corporation
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.